Advert - Boehringer Ingelheim
Promotion of Pradaxa
Date posted12 March 2021
For a misleading claim that Pradaxa 110mg (dabigatran) could be used in any patient at increased risk of bleeding when it was contraindicated in those with severe renal impairment, which risked patient safety, Boehringer Ingelheim was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 7.2 - Making a misleading claim
Clause 9.1 - Failing to maintain high standards.